Drug Discovery

Vivet raises €37.5m to advance gene therapies for metabolic diseases

Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.

Poxel’s diabetes drug Imeglimin succeeds in phase 2b study in Japan

Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan.

Sosei to invest in UK biopharmaceutical firm MiNA Therapeutics

Sosei has agreed to make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company.

AstraZeneca, Pieris form $2.1bn respiratory drug collaboration

AstraZeneca will develop new inhaled respiratory treatments based on Pieris Pharmaceuticals’ Anticalin platform through a collaboration that could generate more than $2bn for the US firm.

Shire licenses dry-eye treatment from Parion Sciences

Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.

Takeda, Harrington to advance development of rare disease therapeutics

Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.

Gates Foundation leads $45.5m round for biotechnology firm Arsanis

Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.

Immune Pharmaceuticals licenses cancer treatment’s Latin America rights to Pint

Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.

Alpine Immune Sciences to merge with Nivalis Therapeutics

Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.